Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 5/20 | 0.53 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17738495 | 0.69 | PLAT (1.00) | PLAT | |
| SCHEMBL16077836 | 0.69 | PLAT (0.47) | PLATKDM4DKDM5A | |
| SCHEMBL31153943 | 0.67 | PLAT (0.45) | PLATKDM4DKDM5A | |
| SCHEMBL16050639 | 0.67 | KDM5A (0.52) | PLATKDM4DKDM5A | |
| SCHEMBL17737914 | 0.66 | PLAT (1.00) | PLAT | |
| SCHEMBL14264666 | 0.66 | PLAT (0.53) | PLATKDM4D | |
| SCHEMBL15658303 | 0.66 | ABL1 (0.43) | PLATKDM4D | |
| SCHEMBL6623532 | 0.66 | PLAT (0.42) | PLATKDM4DKDM5A | |
| SCHEMBL16046587 | 0.66 | KDM4D (0.50) | PLATKDM4D | |
| SCHEMBL16046503 | 0.66 | PLAT (0.44) | PLATKDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785717-B1 | PYRAZOLOPYRROLIDINE COMPOUNDS | NOVARTIS AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-8969341-B2 | Pyrazolopyrrolidine compounds | NOVARTIS AG (CH) | 2015-03-03 | — | — | US | disclosed |
| US-20140350010-A1 | Pyrazolopyrrolidine Compounds | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| EP-2785717-A1 | PYRAZOLOPYRROLIDINE COMPOUNDS | Novartis AG (CH) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013080141-A1 | Pyrazolopyrrolidine compounds | NOVARTIS AG (CH) | 2013-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350010-A1 | Pyrazolopyrrolidine Compounds | MDM4, MDM2, TP53 | PLAT 4090/4885KDM4D 1641/4885MDM4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.